DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
— - 1 Johnson - 1 JP Morgan - 1 Ferring - 1 We've - 1 it's - 1 I've - 1 we've - 1
Top related locs:
Swiss Switzerland
Top related orgs:
Ferring Pharmaceuticals - 1 Service - 1 gastroenterology - 1 Johnson - 1 American Express - 1 Pharma - 1 pharma - 1

Search resuls for: "Ferring Pharmaceuticals"


5 mentions found


☆ In the competitive world of pharma, companies need to focus on worker well-being to retain top talent, says Ferring's HR exec
  + stars: | 2024-10-15 | by ( Julia Hood | ) www.businessinsider.com   time to read: +7 min
She said that Ferring has grown more intentional about focusing on worker well-being, which is particularly important for the highly competitive field of healthcare. What are the benefits for companies focused on worker well-being? We've defined well-being in a holistic way, so it's not just about physical well-being; it's also about mental well-being and financial well-being. What advice do you have for other companies that are just getting started thinking about DEI and worker well-being initiatives? What policies demonstrate your focus on worker well-being?
Persons: —, Johnson, JP Morgan, Ferring, We've, it's, I've, we've, you've Organizations: Ferring Pharmaceuticals, Service, gastroenterology, Johnson, American Express, Pharma, pharma Locations: Swiss, Switzerland
☆ U.S. FDA approves Ferring Pharma's first gene therapy for bladder cancer
  + stars: | 2022-12-16 | by ( ) www.reuters.com   time to read: +1 min
Dec 16 (Reuters) - The U.S. Food and Drug Administration on Friday approved Swiss drugmaker Ferring Pharmaceuticals' first gene therapy for treating adult patients with a type of bladder cancer. The therapy, Adstiladrin, is for patients with an aggressive form of the disease whose current options include having their bladder removed. The treatment, to be administered once every three months into the patient's bladder, triggers the body to make a protein to fight off cancer. Adstiladrin is expected to be commercially available in the United States in the second half of 2023, Ferring said. Bladder cancer is one of the most common cancer in the United States, with non-muscle invasive bladder cancer (NMIBC) representing about 75% of all such cases.
☆ U.S. FDA gives first-ever approval to fecal transplant therapy
  + stars: | 2022-11-30 | by ( ) www.reuters.com   time to read: +2 min
The therapy, Rebyota, targets Clostridium difficile, or C. difficile – a superbug responsible for infections that can cause serious and life-threatening diarrhea. While this is the first such therapy approved by the Food and Drug Administration (FDA) for recurrent C. difficile infections, fecal microbiota transplants – classified by the regulator as investigational – have long been the standard of care in the U.S. for this condition. Approval for the therapy comes on the back of a positive vote from the regulator's advisers in September, as most on the panel sought standardization of the therapy. Ferring, which gained the therapy through its 2018 purchase of U.S.-based Rebiotix Inc, was not immediately available for a comment on pricing and availability of the therapy. Besides Ferring, other companies including Seres Therapeutics (MCRB.O), which is developing an oral treatment, are working on similar therapies based on fecal microbiota transplantation.
☆ It's 'early innings' in the fertility market. Here's how to play the booming business with under-the-radar names
  + stars: | 2022-11-17 | by ( Michelle Fox | ) www.cnbc.com   time to read: +13 min
The multibillion dollar global fertility market is ripe with opportunity. For investors thinking about the fertility market, pharma firms may come to mind. In fact, the number of employers looking at fertility benefits as a "must have" has skyrocketed, she said. The global market size for fertility within the private women's health market should reach $72 billion by 2027, a report by FemTech Focus and Coyote Ventures found. Just like there were a wave of fintech companies going public, she expects fertility companies to eventually follow suit.
☆ Ferring Pharmaceuticals has suspended shipments of a key fertility drug, Menopur
  + stars: | 2022-10-27 | by ( Cheryl Teh | ) www.businessinsider.com   time to read: +2 min
Ferring Pharmaceuticals has suspended all shipments of its key fertility drug, Menopur. Insider obtained a memo Ferring Pharmaceuticals sent to healthcare providers. Insider received a copy of a memo Ferring Pharmaceuticals' chief science officer Elizabeth Garner sent to healthcare providers on Wednesday, announcing the stoppage of Menopur shipments. Garner said "all shipments" of the drug have been suspended "due to changes made in the manufacturing process of Menopur drug substance by a third-party supplier." A staff member at Ferring Pharmaceutical's Singapore division confirmed to Insider on Thursday that shipments of Menopur are suspended worldwide.
0 next >>
Total: 5